Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Sees Large Drop in Short Interest

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totaling 9,551 shares, a drop of 83.7% from the July 15th total of 58,489 shares. Based on an average daily volume of 481,032 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the company’s shares are sold short.

Oncotelic Therapeutics Trading Up 2.3%

OTLC opened at $0.04 on Wednesday. The company has a fifty day moving average price of $0.04 and a two-hundred day moving average price of $0.05. Oncotelic Therapeutics has a 1-year low of $0.01 and a 1-year high of $0.11. The company has a market cap of $15.98 million, a P/E ratio of 0.06 and a beta of -0.23. The company has a current ratio of 0.11, a quick ratio of 0.11 and a debt-to-equity ratio of 0.01.

About Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.